Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Management of Symptomatic Uncomplicated Diverticular Disease (SUDD) of the Colon With Clostridium Butyricum CBM588® Versus Rifaximin: Results From a Real-World Retrospective Italian Study

NCT06852274 is registered in ClinicalTrials.gov with Dr. Amjad Khan as lead sponsor.

NCT NCT06852274
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06852274 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Management of Symptomatic Uncomplicated Diverticular Disease (SUDD) of the Colon With Clostridium Butyricum CBM588® Versus Rifaximin: Results From a Real-World Retrospective Italian Study
Lead sponsor
Dr. Amjad Khan
Phase
Not applicable
Overall status
Completed
Start date
March 1, 2023
Completion date
October 31, 2024
Enrollment
70 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diverticular diseases, gastro-intestinal disorder